Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT07368985
Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer
A Phase II Single Arm Open Label Study of Pembrolizumab and Lenvatinib in Patients With High Risk Locally Advanced Cervix Cancer: an EMBRACE High Risk Study Initiative
Sponsor: Merck Sharp & Dohme LLC
Conditions
Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2 Cervical Cancer by FIGO Stage 2018 Squamous Cell Carcinoma FIGO 2018 Stage IIIA, IIIB, IIIC1-IIIC2
Interventions
pembrolizumab and lenvatinib
Updated 1 time since 2026 Last updated: Jan 23, 2026 Started: Mar 31, 2026 Primary completion: Oct 31, 2029 Completion: Oct 31, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Adenocarcinoma or Adeno-squamous Carcinoma Stage IB3-IIIC2 and Cervical Cancer by FIGO Stage 2018, this trial is actively recruiting participants. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 1 data snapshot since 2026. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Merck Sharp & Dohme LLC
- Prof. Dr. Remi A. Nout
Data source: Erasmus Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .